Findings

What do systematic reviews say?

42 questions · 42 findings · 3 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 26.2%GRADE not reported 2 · 4.8%Very low 7 · 16.7%Low 15 · 35.7%Moderate 7 · 16.7%High 0 · 0%

Macrolides vs no intervention

Hospitalisation ‐ not reported · children with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs placebo

Hospitalisation (any cause) · adults with bronchiectasis

Macrolides showed no clear difference in hospitalisation: all cause compared with placebo (low certainty).

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
OR 0.56 [0.19, 1.62]
2 studies · 151 participants
Low

Macrolides vs no intervention

Serious adverse events ‐ not reported · children with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs no intervention

All‐cause mortality · children with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Macrolides vs no intervention

Quality of life ‐ not reported · children with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs placebo

Serious adverse events · adults with bronchiectasis

Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
OR 0.49 [0.2, 1.23]
3 studies · 326 participants
Low

Macrolides vs placebo

All‐cause mortality · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 540 participants
Low

Macrolides vs placebo

Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Moderate

Macrolides vs placebo

Quality of life: change · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 305 participants
Low

Macrolides vs no intervention

Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults with bronchiectasis

Macrolides showed no clear difference in ≥ 1 exacerbation compared with no intervention (moderate certainty).

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
OR 0.31 [0.08, 1.15]
1 study · 43 participants
Moderate

Macrolides vs no intervention

Hospitalisation ‐ not reported · adults with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs no intervention

Serious adverse events ‐ not reported · adults with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolide+tetracycline vs macrolides

Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 187 participants
Very low

Macrolide+tetracycline vs macrolides

All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1 [0.52, 1.93]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 182 participants
Very low

Macrolide+tetracycline vs macrolides

All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1.63 [0.38, 7.02]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quinolone vs macrolides

Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease

Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with macrolide (low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1 [0.32, 3.1]
1 study · 50 participants
Low

Macrolides vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Macrolides vs tetracycline

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found